Breast Cancer in Young Women and its Impact on Reproductive Function

Loman, 2001, Family history of breast and ovarian cancers and BRCA 1 and BRCA2 mutations in a population-based series of early-onset breast cancer, J Natl Cancer hist, 93, 1215, 10.1093/jnci/93.16.1215 Weitzel, 2003, Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis, Arch Surg, 138, 1323, 10.1001/archsurg.138.12.1323 Hartmann, 2001, Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers, J Natl Cancer inst, 93, 1633, 10.1093/jnci/93.21.1633 Rebbek, 2005, Effect on short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Gin Oncol, 23, 7804, 10.1200/JCO.2004.00.8151 Bermejo-Perez, 2007, Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review, Int J Cancer, 121, 225, 10.1002/ijc.22817 Kauff, 2007, Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2, J Clin Oncol, 25, 2921, 10.1200/JCO.2007.11.3449 Allred, 2004, The origins of estrogen receptor alpha-positive and estrogen receptor alphanegative breast cancer, Breast Cancer Res, 6, 240, 10.1186/bcr938 Eisen, 2005, Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study, J Clin Oncol, 23, 7491, 10.1200/JCO.2004.00.7138 Levine, 2003, Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations, J Clin Oncol, 21, 4222, 10.1200/JCO.2003.04.131 Callahan, 2007, Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction, J Clin Oncol, 25, 3985, 10.1200/JCO.2007.12.2622 Axelrod, 2008, Breast cancer in young women, J Am Coll Surg, 206, 1193, 10.1016/j.jamcollsurg.2007.12.026 Thewes, 2005, Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer, J Clin Oncol, 23, 5155, 10.1200/JCO.2005.07.773 Lee, 2006, American Society of Clinical Oncology recommendations on fertility preservation in cancer patients, J Clin Oncol, 24, 2917, 10.1200/JCO.2006.06.5888 Oktay, 2006, Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy, J Clin Endocrinol Metob, 91, 3885, 10.1210/jc.2006-0962 Oktay, 2006, Measuring the impact of chemotherapy on fertility in women with breast cancer, J Clin Oncol, 24, 4044, 10.1200/JCO.2006.06.9823 Oktay, 2004, Live birth after cryopreserved ovarian tissue auto transplantation, Lancet, 364, 2091, 10.1016/S0140-6736(04)17541-7 Oktem, 2007, Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function, Cancer, 110, 2222, 10.1002/cncr.23071 Partridge, 2007, Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from international Breast Cancer Study Group Trials V and VI, Eur J Cancer, 43, 1646, 10.1016/j.ejca.2007.04.006 Gadducci, 2007, Ovarian function and childbearing issues in breast cancer survivors, Gynecol Endocrinol, 23, 625, 10.1080/09513590701582406 Tham, 2007, The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane, Am J Clin Oncol, 30, 126, 10.1097/01.coc.0000251398.57630.4f Alton, 2004, Chemotherapy-related amenorrhea (CRA) in breast cancer survivors: impact of taxanes on ovarian function, Breast Cancer Res Treat, 88, S61 Duffy, 2005, Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy, J Clin Oncol, 23, 766, 10.1200/JCO.2005.01.134 Mourits, 2001, Tamoxifen treatment and gynecologic side effects: a review, Obstet Gynecol, 97, 855, 10.1016/S0029-7844(00)01196-0 Barthelmes, 2004, Tamoxifen and pregnancy, Breast, 13, 446, 10.1016/j.breast.2004.08.007 Oktay, 2005, Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation, J Clin Oncol, 23, 4347, 10.1200/JCO.2005.05.037 Bukulmez, 2004, Assessment of ovarian reserve, Curr Opin Obstet Gynecol, 16, 231, 10.1097/00001703-200406000-00005 Broekmans, 2006, A systematic review of tests predicting ovarian reserve and IVF outcome, Hum Reprod Update, 12, 685, 10.1093/humupd/dml034 Lutchman Singh, 2005, Fertility in female cancer survivors: pathophysioiogy, preservation and the role of ovarian reserve testing, Hum Reprod Update, 11, 69, 10.1093/humupd/dmh052 Anderson, 2006, The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer, Hum Reprod, 21, 2583, 10.1093/humrep/del201 Sonmezer, 2004, Fertility preservation in female patients, Hum Reprod Update, 10, 251, 10.1093/humupd/dmh021 Blumenfeld, 2007, How to preserve fertility in young women exposed to chemotherapy?, The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries, Oncologist, 12, 1044 Azim, 2008, Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study, J Clin Oncol, 26, 2630, 10.1200/JCO.2007.14.8700 Jasper, 2008, Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth, Prenat Diagn, 28, 292, 10.1002/pd.1925 Ives, 2007, Pregnancy after breast cancer: population based study, BMJ, 334, 194, 10.1136/bmj.39035.667176.55 Velentgas, 1999, Pregnancy after breast carcinoma: outcomes and influence on mortality, Cancer, 85, 2424, 10.1002/(SICI)1097-0142(19990601)85:11<2424::AID-CNCR17>3.0.CO;2-4 Blakely, 2004, Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence, Cancer, 100, 465, 10.1002/cncr.11929 Kroman, 1997, Should women be advised against pregnancy after breast-cancer treatment?, Lancet, 350, 319, 10.1016/S0140-6736(97)03052-3 Barhelmes, 2005, Pregnancy and breast cancer, BMJ, 330, 1375, 10.1136/bmj.330.7504.1375 Cardonick, 2004, Use of chemotherapy during human pregnancy, Lancet Oncol, 5, 283, 10.1016/S1470-2045(04)01466-4 Mintzer, 2002, Breast cancer in the very young patient a multidisciplinary case presentation, Oncologist, 7, 547, 10.1634/theoncologist.7-6-547 Aviles, 2001, Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero, Clin Lymphoma, 2, 173, 10.3816/CLM.2001.n.023 Averette, 1999, Pregnancy after breast carcinoma: the ultimate medical challenge, Cancer, 85, 2301, 10.1002/(SICI)1097-0142(19990601)85:11<2301::AID-CNCR1>3.0.CO;2-A Cella, 2008, Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy, Breast Cancer Res Treat, 107, 167, 10.1007/s10549-007-9548-1 Andrieu, 2006, Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS), J Natl Cancer Inst, 98, 535, 10.1093/jnci/djj132 Moran, 2005, Effects of breast-conserving therapy on lactation after pregnancy, Cancer, 11, 399, 10.1097/00130404-200509000-00007 Santoro, 2004, What a SWAN can teach us about menopause, Contemp Obstet/Gynecol, 49, 69 Howeil, 2005, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet, 365, 60, 10.1016/S0140-6736(04)17666-6 Andersen, 2007, Sexual well-being among partnered women with breast cancer recurrence, J Clin Oncol, 25, 3151, 10.1200/JCO.2006.09.6958 Holmberg, 2004, HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped, Lancet, 363, 453, 10.1016/S0140-6736(04)15493-7 Von Schoultz, 2005, Menopausal hormone therapy after breast cancer: the Stockholm randomized trial, J Natl Cancer Inst, 97, 533, 10.1093/jnci/dji071 Sestak, 2006, Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms, J Clin Oncol, 24, 3991, 10.1200/JCO.2005.04.3745 Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal Women: principal results from the Women's Healthinitiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Holmberg, 2008, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst, 100, 475, 10.1093/jnci/djn058 Chiarelli, 2006, Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection, Cancer Epidomiol Biomarkers Prev, 15, 1856, 10.1158/1055-9965.EPI-06-0290 Bordeleau, 2007, Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review, Clin Ther, 29, 230, 10.1016/j.clinthera.2007.02.006 Anderson, 2004, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701 Madalinska, 2006, The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylacticsaipingo-oophorectomy, J Clin Oncol, 24, 3576, 10.1200/JCO.2005.05.1896 Rebbeck, 2005, Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, J Clin Oncol, 23, 7804, 10.1200/JCO.2004.00.8151 Metcaife, 2007, Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation, Clin Genet, 72, 208, 10.1111/j.1399-0004.2007.00859.x